Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / DCPH - Deciphera's Ripretinib In 2nd Line GIST: An Assessment

DCPH - Deciphera's Ripretinib In 2nd Line GIST: An Assessment

Deciphera Pharmaceuticals Inc.
  • DCPH has seen some early success with ripretinib in 4th line and later GIST.
  • However, the key to the mint is to show positive data in INTRIGUE, in 2nd line GIST for imatinib-refractory patients, and compared to sunitinib.
  • That data will be out sometime in late 2021.

For further details see:

Deciphera's Ripretinib In 2nd Line GIST: An Assessment
Stock Information
Company Name: Deciphera Pharmaceuticals Inc.
Stock Symbol: DCPH
Market: NASDAQ
Website: deciphera.com
Menu
DCPH DCPH Quote DCPH Short DCPH News DCPH Articles DCPH Message Board
Get DCPH Alerts

News, Short Squeeze, Breakout and More Instantly...